PK Parameter Comparison
Select 2-5 drugs to generate a side-by-side comparison table of key pharmacokinetic parameters: half-life, bioavailability, volume of distribution, protein binding, primary metabolism enzymes, and excretion route. Ideal for comparing drugs within the same therapeutic class.
Disclaimer: This tool is for educational purposes only. Always consult a healthcare professional for medication decisions.
| Parameter | Ratio (A/B) | Advantage | ||
|---|---|---|---|---|
Clinical Notes
- •
Understanding Pharmacokinetic Parameters
Pharmacokinetic (PK) parameters describe how the body handles a drug over time. Cmax is the peak plasma concentration achieved after a dose, reflecting the rate and extent of absorption. Tmax is the time to reach Cmax and indicates absorption speed. AUC (area under the concentration-time curve) represents total systemic drug exposure and is proportional to the absorbed dose divided by clearance. Half-life (t½) governs the rate of elimination and determines dosing frequency and time to steady state.
Comparing PK parameters is fundamental in bioequivalence studies (generic drug approval), formulation optimization (immediate-release vs. extended-release), dose selection, and therapeutic drug monitoring. The FDA considers two formulations bioequivalent when the 90% confidence interval for the ratio of AUC and Cmax falls within 80–125%. This standard ensures that generic drugs deliver comparable exposure to the reference product.
Bioavailability (F) indicates the fraction of an administered dose that reaches systemic circulation. Intravenous drugs have F = 100% by definition. Oral bioavailability is reduced by incomplete absorption, intestinal metabolism, and first-pass hepatic extraction. Comparing bioavailability across drugs within the same class helps predict dose equivalence and informs switching between formulations or routes of administration.
How to Use
-
1
Select drugs for comparison
Choose two or more drugs from the database for pharmacokinetic parameter comparison. The tool retrieves key PK parameters from FDA clinical pharmacology sections of approved prescribing information, including bioavailability (F), time to peak concentration (Tmax), volume of distribution (Vd), clearance (CL), half-life (t½), and protein binding.
-
2
View side-by-side PK parameter table
The comparison table displays parameters for each drug in standardized units with reference to the patient population studied (healthy adults, renal impairment cohorts, or pediatric populations) and the route of administration. Parameters are annotated with ranges where population variability data is available.
-
3
Interpret clinical implications
Use the comparison to identify PK-based differences in dosing frequency requirements, dose adjustment needs in renal or hepatic impairment, interaction potential, and monitoring needs. Parameter differences within a drug class (e.g., comparing DOAC half-lives or statin bioavailabilities) inform therapeutic substitution and adherence counseling.
About
Comparative pharmacokinetic analysis enables systematic evaluation of how structurally or mechanistically related drugs differ in their absorption, distribution, metabolism, and excretion profiles — differences that translate into distinct dosing requirements, interaction profiles, and patient-specific utility. Within a drug class, PK parameter differences often drive formulary decisions, especially when therapeutic efficacy is similar across class members and differentiation is based primarily on pharmacokinetic convenience, safety, or drug interaction profile.
FDA clinical pharmacology review, the basis for the pharmacokinetic information published in drug prescribing information, evaluates PK parameters from phase I dose-escalation studies, mass balance studies, drug interaction studies, and population PK analyses from phase II/III trials. The resulting parameters represent population mean values with measures of variability derived from healthy adult volunteers or patient populations. The FDA's Summary of Clinical Pharmacology Studies, accessible through Drugs@FDA, provides detailed quantitative PK data and inter-individual variability estimates that serve as the reference for this comparison tool.
This PK parameter comparison tool aggregates FDA-approved pharmacokinetic parameters for direct comparison across drugs, enabling visualization of differences in half-life, bioavailability, protein binding, volume of distribution, and clearance within and across drug classes. Comparative displays highlight clinically actionable differences — such as the substantially longer half-life of apixaban compared to rivaroxaban that influences once versus twice-daily dosing, or the lower protein binding of levetiracetam compared to phenytoin that reduces interaction risk in polypharmacy epilepsy regimens. Parameter comparisons are intended to support pharmacist counseling, therapeutic substitution decisions, and pharmaceutical education.